Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.

摘要: Purpose To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate brachytherapy using an automated delivery system (IO-LDRB). Methods and Materials Between 2003 2013, 2608 patients from 3 centers were IO-LDRB as single-modality treatment for low or low-tier intermediate-risk cancer. Databases the have been analyzed. These independent databases collected prospectively. Patient, tumor, characteristics then compared, Kaplan-Meier survival estimates of relapse–free (bRFS) generated, Cox proportional hazards model was used to determine factors predicting relapse. Results A total a median follow-up 4.7 (interquartile range, 3.1-6.9) years Median age 64 (range, 42-84) years. In these patients, initial prostate-specific antigen 5.5 ng/mL, 74% T1, 26% T2; 73% Gleason 6, 25% 7. percentage biopsy cores positive 33%, gland volume 34.2 cm3. Eleven percent received hormones 3.0 months before implantation. seed activity 0.437 mCi, D90 (dose covering 90% volume) 186.7 Gy, V100 99.37%. Biochemical relapse observed 124 (4.8%), time failure 4.0 years. Predicted bRFS 93% at 7 years. On regression dependent only on implantation density. Conclusions This study demonstrates that is effective option Rates remain several after treatment. results compared favorably published manual preplan technique results.